pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice
Open Access
- 11 December 2015
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 5 (12) , e374
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacyMolecular and Cellular Probes, 2013
- MyD88: A Critical Adaptor Protein in Innate Immunity Signal TransductionThe Journal of Immunology, 2013
- High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsBlood, 2011
- Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up DataJournal of Clinical Oncology, 2010
- Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceBlood, 2010
- DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse modelBlood, 2010
- Immunogenic cancer cell death: a key-lock paradigmCurrent Opinion in Immunology, 2008
- Frequent antibody production against RAR in both APL mice and patientsBlood, 2006
- New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell populationBlood, 2004
- PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemiaNature Medicine, 2003